Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Humacyte earnings update and stock context

Humacyte (HUMA) reported second quarter 2026 results that included revenue of US$0.406 million and a net loss of US$36.8 million, alongside recent Nasdaq compliance pressure after its share price stayed below US$1.00.

For the first half of 2026, the company reported revenue of US$0.901 million and a net loss of US$54.42 million. Earnings per share moved from a small profit a year ago to a basic loss of US$0.25 from continuing operations.

Humacyte also received a Nasdaq notice on July 31, 2026 after the stock traded below US$1.00 for about a month. The company has until January 27, 2027 to regain compliance by lifting its closing bid to at least US$1.00 for 10 consecutive trading days.

Alongside these financial and listing updates, Humacyte highlighted interim Phase III data for its acellular tissue engineered vessel in dialysis access and early hospital uptake for its SYMVESS vascular repair product. These clinical and commercial developments frame much of the current discussion around the stock.

See our latest analysis for Humacyte.

Humacyte's latest earnings miss, Nasdaq compliance notice and mixed clinical headlines have coincided with pressure on the stock, with the share price down 31.79% year to date and the 1 year total shareholder return down 62.64%. This signals fading momentum despite selected trial progress.

If Humacyte's recent moves have you reassessing risk and opportunity in healthcare, this could be a good moment to scan for other ideas using our 43 healthcare AI stocks

With Humacyte now trading below US$1.00 after a steep 1 year decline, some investors may see a speculative entry, while others prefer to wait for clearer progress. How does the current valuation frame that choice?

Most Popular Humacyte Narrative: 83.4% Undervalued

Humacyte's most widely followed valuation narrative points to a fair value of $4.00 against the recent $0.67 close, which implies a steep gap that hinges on aggressive long term assumptions and a higher future earnings multiple.

Positive Phase III results for the ATEV in dialysis access, targeting women and high risk men who represent more than half of the dialysis population, align with a large, chronically treated patient group that could influence longer term revenue and earnings if an added indication is approved.

Read the complete narrative.

Want to see what sits behind that dialysis push and the $4.00 fair value tag? The narrative leans heavily on rapid revenue expansion, margin uplift and a richer earnings multiple than many established biotechs.